Palo Alto, United States
Exai Bio, founded in 2021, is pioneering a next-generation liquid biopsy platform to support early detection and precise diagnosis of cancer, aligning with its mission to innovatively target cancer treatment. By leveraging proprietary RNA and artificial intelligence technology, the company promises transformational insights into cancer biology.
Built with expertise and leadership from prestigious institutions such as UCSF, Stanford, and MIT, coupled with practical industry experience from entities like Bluestar and Google, Exai Bio capitalizes on the convergence of RNA biology and AI/machine learning.
Supported by top-tier investors, including Section 32, Casdin Capital, and Two Sigma Ventures, the company secured a $71.46M early-stage investment as of October 2022. Headquartered in the United States, Exai Bio emphasizes core values such as integrity, openness, and teamwork, fostering a robust culture poised for impactful advancements in biotechnology and healthcare.
